购物车
- 全部删除
- 您的购物车当前为空
AZD7325 (AZD-7325) 是具有口服活性的α2和α3受体正向别构调节剂,Ki 分别是 0.3 和 1.3 nM。它是中等 CYP1A2和强效 CYP3A4诱导剂,有用于焦虑和 dravet 综合征相关的研究潜力。
为众多的药物研发团队赋能,
让新药发现更简单!
AZD7325 (AZD-7325) 是具有口服活性的α2和α3受体正向别构调节剂,Ki 分别是 0.3 和 1.3 nM。它是中等 CYP1A2和强效 CYP3A4诱导剂,有用于焦虑和 dravet 综合征相关的研究潜力。
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
1 mg | ¥ 228 | 现货 | |
5 mg | ¥ 578 | 现货 | |
10 mg | ¥ 872 | 现货 | |
25 mg | ¥ 1,580 | 现货 | |
50 mg | ¥ 2,660 | 现货 | |
100 mg | ¥ 3,930 | 现货 | |
1 mL x 10 mM (in DMSO) | ¥ 638 | 现货 |
产品描述 | AZD7325 (AZD-7325) is a GABA-Aα2,3 -selective receptor modulator. |
体内活性 | AZD7325 on synaptic responses was more prominent in mice on the 129S6/SvEvTac background strain that has been demonstrated to be seizure resistant in the model of Dravet syndrome (Scn1a+/?) and in which the α2 GABAA receptor subunits are higher relative to in the C57BL/6J strain.?Consistent with this, treatment of mice with AZD7325 is associated with a higher temperature threshold for hyperthermia-induced seizures in Scn1a+/? mice without apparent sedative effects.?Our results in a model system indicate that selective targeting α2 is a potential therapeutic option for Dravet syndrome[1]. |
动物实验 | Animal Model:Male and female P18 - P20 F1.Scn1a+/- mice. Dosage:10, 17.8 or 31.6 mg/kg. Administration:Oral administration[1] |
别名 | AZD-7325 |
分子量 | 354.38 |
分子式 | C19H19FN4O2 |
CAS No. | 942437-37-8 |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||
溶解度信息 | DMSO: 9 mg/mL (25.4 mM) | |||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||
DMSO
|
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.